Remove 2026 Remove Clinic Remove Treatment
article thumbnail

Laser focus boosting athletic performance with low-level laser therapy

Chiropractic Economics

This is a fundamental change in the clinical toolbox that will allow healthcare providers to deliver a higher level of service and enhanced clinical outcomes to their patient populations. We can’t wait to see what he does in 2026. as quickly as possible. during the 2012 Summer Olympics in London in 2012.

Ligaments 264
article thumbnail

Osteochondritis Dissecans of the Knee

Orthopedic Principles

Courtesy: Prof Michael Hantes, ESSKA 1st Vice President Ivory Orange Modern Meet Our Team Instagram Post – 1 Lecture Topic: Osteochondritis Dissecans of the Knee Aim: Define the treatment algorithm for this disease. Clinical Presentation & Diagnosis Symptoms: Knee pain after prolonged activity. Patella (5-10%).

X-ray 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Explore the potential health benefits of chaga

Chiropractic Economics

The potent antioxidant capabilities of chaga offer patients incredible clinical benefits. The potent antioxidant capabilities of chaga offer patients incredible clinical benefits. When it comes to clinical application, more oxidative stress will make healing from injury nearly impossible.

Health 147
article thumbnail

OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment

OrthoSpineNews

OrthoPreserve’s implant addresses a significant treatment gap that exists due to the poor outcomes of the standard of care for meniscus tears, a partial meniscectomy, which removes the damaged tissue. OrthoPreserve’s proprietary technology has the potential to disrupt the standard of care and displace more invasive treatments.

article thumbnail

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

OrthoSpineNews

Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements Pivotal CLARITY trial fully funded with initial interim results expected in Q2 2026 BROOMFIELD, Colo.,

Spine 52